Rilmenidine modulates intracellular calcium ions by activation of the imidazoline I-1 receptor, increasing phosphorylation of p38 and the expression of nuclear receptor farnesoid X receptor (FXR), leading to reduced levels of hepatic steatosis in mice and cell steatosis in HepG2 HCC cells [159]. Here, NR1H4 is linked to fatty liver disease.